NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced the appointment of Julie Bauman, MD, MPH as the new Chair of the organization’s Cancer Prevention and Control (CPC) Committee. She previously served as the committee’s Vice Chair.
Dr. Bauman is the director of the George Washington (GW) University Cancer Center, the associate dean of cancer, and a professor of medicine at the GW School of Medicine and Health Sciences. Her research focuses on biomarker-driven, early-phase clinical trials intended to prevent or improve oncologic outcomes in head and neck cancer. Currently, Dr. Bauman is the Multiple Principal Investigator (MPI) of the University of Arizona Cancer Prevention Clinical Trials Network, which performs early-phase cancer prevention trials evaluating surrogate biomarker modulation by candidate chemoprevention agents across multiple organ sites. She currently serves as the Co-Chair of the NCI Cancer Prevention Steering Committee and the Co-Chair of the Previously Untreated Locally Advanced (PULA) Task Force of the NCI Head and Neck Cancer Steering Committee.
The NRG CPC Committee is centered around cancer prevention priorities such as reducing cancer risk through optimal screening, biomarker evaluation, and risk reduction strategies in NRG research. The CPC Committee is part of NRG’s NCI Community Oncology Research Program (NCORP) research base.
